[HTML][HTML] Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco, SV Konstantinides - Research and Practice in …, 2021 - Elsevier
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
[HTML][HTML] Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco, SV Konstantinides - pillintrip.com
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
AC Mavromanoli, S Barco… - Research and Practice in …, 2021 - europepmc.org
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco… - Research and Practice …, 2021 - Wiley Online Library
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
[PDF][PDF] Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
MD Stefano Barco, SV Konstantinides - 2021 - researchgate.net
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco… - Research and Practice in …, 2021 - zora.uzh.ch
Direct oral anti-activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco… - Research and Practice …, 2021 - search.proquest.com
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
[HTML][HTML] Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco… - Research and Practice …, 2021 - ncbi.nlm.nih.gov
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco… - … and practice in …, 2021 - pubmed.ncbi.nlm.nih.gov
Direct oral anti-activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …
[HTML][HTML] Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
AC Mavromanoli, S Barco… - Research and Practice in …, 2021 - rpthjournal.org
Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K
antagonists as the standard of care in treatment of venous thromboembolism. However …
antagonists as the standard of care in treatment of venous thromboembolism. However …